German manufacturer JRS Pharma has announced the construction of a new manufacturing facility in Cedar Rapids, Iowa.
Starting in the fall of 2022, with operations commencing in early 2024, the expansion will be a two-story precast building that will manufacture microcrystalline cellulose products.
As market demands continue to grow, JRS is dedicated to adding additional production capacity to meet its customers' needs. This new facility will add additional capacity in Cedar Rapids, Iowa, at their existing 725 41st Avenue Drive site. The project will also include a new production line for various MCC products. It will add a number of new high-value jobs with positions in operations, maintenance, warehouse, and quality.
JRS Pharma, a member of J. Rettenmaier & Söhne Group (JRS), has multiple manufacturing facilities worldwide, including Cedar Rapids - Iowa, Nastola - Finland, Changzhou - China, Ahmedabad - India, and Weissenborn - Germany.
